Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise. TAVR has seen significant advancements in the treatment<a href="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...</a>
The TIME study, presented by Dr. Thomas MacDonald, is a randomized study of over 21,000 patients with high blood pressure with a follow-up beyond 5 years. As is widely known, high blood pressure is the leading global cause of early death, accounting for nearly 10 million deaths in 2015, of which 4.9 million were caused by<a href="https://solaci.org/en/2022/08/29/esc-2022-time-study-3/" title="Read more" >...</a>
Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising. TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been<a href="https://solaci.org/en/2022/08/26/tavr-in-bicuspid-patients-are-outcomes-the-same-in-men-and-women/" title="Read more" >...</a>
In bicuspid patients with aortic stenosis and low surgical risk, transcatheter aortic valve replacement (TAVR) with balloon expandable valve offers results comparable to normal anatomy results. These data come from the TVT registry, presented at EuroPCR 2021 scientific sessions. Stroke and death rates (inhospital, 30 days and one year) in bicuspid patients did not result<a href="https://solaci.org/en/2021/05/27/europcr-2021-tvt-registry-outcomes-of-tavr-in-low-surgical-risk-bicuspids/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. TAVR has matured over time and has advanced onto low risk patients, but one of its greatest challenges continues to be bicuspid valve patients. These represent between 1% and 2% of the population and over 20% of young adults requiring surgical valve replacement (SAVR). The study looked at 27,086 patients<a href="https://solaci.org/en/2020/08/28/good-evolution-of-bicuspid-valves-with-evolute-or-evolute-pro/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Bicuspid aortic valves are found in approximately 2% of patients and represent the most frequent cause of aortic stenosis in young adults requiring valve replacement. Though TAVR has advanced significantly, this entity has not yet been included in the different randomized studies. At present, we have data from different reports,<a href="https://solaci.org/en/2020/08/21/sapien-3-good-outcomes-in-bicuspids/" title="Read more" >...</a>
This large registry has shown bicuspid aortic stenosis (AS) patients have similar mortality with transcatheter aortic valve replacement (TAVR) compared against surgical valve replacement (SAVR). TAVR outcomes in this population are not only similar to SAVR outcomes, but also to TAVR outcomes in patients with conventional aortic valve anatomy. Despite the good news, these outcomes<a href="https://solaci.org/en/2019/11/15/temporal-trends-and-outcomes-of-tavr-in-bicuspids-are-we-any-better/" title="Read more" >...</a>
Myocardial revascularization surgery is still one of the most effective treatment strategies against coronary disease. One of the most important advantages of surgery over angioplasty is the chance to reach complete revascularization. This has proven to improve the survival of patients and to reduce the number of cardiovascular events. The choice of conduit for the<a href="https://solaci.org/en/2019/09/26/best-conduits-and-best-surgeons-for-the-best-outcome/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients<a href="https://solaci.org/en/2019/09/24/tavr-in-bicuspid-has-the-same-results-in-surgery-at-hospital-level/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution. A meta-analysis of 12 studies with a total 41485 patients was carried out. <a href="https://solaci.org/en/2019/04/16/is-tricuspid-regurgitation-after-tavr-significant/" title="Read more" >...</a>